PI3K Inhibitors: Novel Molecular-Targeted Drug Candidates for Cancer Therapy

Dexin Kong*
Department of Molecular-targeted Anticancer Drug Discovery, School of Pharmaceutical Sciences and Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China

As an exciting information, some phase I data of the most advanced PI3K inhibitors such as GDC-0941 have been available, which indicate that patients generally tolerate these drug candidates, demonstrating their safety. As the remaining clinical trials go forward [16], the first PI3K inhibitor is expected to appear in clinic in the near future.

Acknowledgments
This work was supported by a grant from The Natural Science Foundation from Tianjin (12JCZDJC25800), a grant from “211” project of Tianjin Medical University, and a grant from Japan Society for the Promotion of Science (FY2012, S-12105).

References
2. Kang S, Denley A, Vanhaesebroeck B, Vogt PK (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of PI3K. Anticancer Drug Discovery, School of Pharmaceutical Sciences and Research Center of Basic Medical Sciences, Tianjin Medical University, 22 Qi-Xiang-Tai Rd, Heping, Tianjin 300070, China; Tel: 86-22-23542805; Fax: 86-22-2354-2775; E-mail: kongdexin@tjmu.edu.cn

Received June 12, 2012; Accepted June 12, 2012; Published June 14, 2012


*Corresponding author: Dexin Kong, Department of Molecular-Targeted Anticancer Drug Discovery, School of Pharmaceutical Sciences and Research Center of Basic Medical Sciences, Tianjin Medical University, 22 Qi-Xiang-Tai Rd, Heping, Tianjin 300070, China; Tel: 86-22-23542805; Fax: 86-22-2354-2775; E-mail: kongdexin@tjmu.edu.cn

© 2012 Kong D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


